Search This Blog

Friday, March 15, 2019

Quorum Health’s losses top $200M in 2018

  • Quorum Health reported a $200.2 million loss for the last calendar year, 75% larger than its $114.2 million loss in 2017.
  • Net operating revenue totaled $1.88 billion, down 9.3% from $2.07 billion the previous year — reflecting the Brentwood, Tennessee-based company’s recent downsizing. During the year, Quorum divested three hospitals and closed another one.
  • For the three months ended Dec. 31, revenue slid 12% year over year to $458.6 million, and same-facility admissions dropped 1.1% versus the fourth quarter of 2017.

Like many health systems, Quorum is seeking to stabilize its ship against rough financial headwinds and is shedding hospitals to reduce its debt. Thus far, the company has collected about $87 million in proceeds from hospital sales and has indicated plans to sell an additional $215 million in assets by the end of this year.
In the third quarter, Quorum tightened its belt further, laying off 120 employees and 22 doctors and discontinuing four service lines. The 27-hospital system also exited or renegotiated several managed care contracts.
Quorum attributed the decline in same-facility net patient revenues during the fourth quarter to lower volumes as a result of those actions.
The austerity moves seem to be helping. Quorum reported net loss for the fourth quarter of $20.7 million, down from $26.8 million the previous year. Adjusted EBITDA was $37.5 million for the quarter and $126.4 million for the year, down from $49 million and $141.8 million, respectively.
“Over the course of 2018, we significantly improved our EBITDA margins through targeted efficiency initiatives, and divested three hospitals, which brought us closer to our refinancing goal,” Quorum President and CEO Robert Fish said in a statement included in the financial report filed with the Securities and Exchange Commission. “In addition, we have strengthened our management team by adding experienced leadership in many key areas of our business.”
Since spinning off from Community Health Systems in 2016, Quorum has sold 10 hospitals. A definitive agreement to sell Scenic Mountain Medical Center in Big Spring, Texas, is expected to close by the end of April, with more divestitures planned by the end of the year.

HCA defies industry trends with 19 straight quarters of admission gains

HCA has been a Wall Street favorite for a while, bucking industry trends with admissions and revenue growth.
The Nashville-based chain boasted 19 consecutive quarters of rising admissions in its most recent earnings report, a feat given the volatility some of its competitors have experienced. By contrast, Community Health Systems and Tenet both reported slumps in patient volume in the most recent quarter. UHS also has seen volume growth but has a much smaller footprint of acute care hospitals.
The streak comes as hospital operators face headwinds leaning on patient volumes, including a shift to lower-cost care settings, payer pressures and relative shifts from commercial to government patients. A few key strategies have boosted HCA’s continued admissions growth — from picking the right markets to successfully riding the trend to care outside hospital walls, analysts say.
Presence in growing cities, investment in ancillary services and physician recruitment are among the drivers of admissions growth, Brian Tanquilut, an analyst with Jefferies, told Healthcare Dive.
For example, HCA has a large footprint in Nashville, Houston and Dallas — all regions that have captured significant population growth in recent years. Big and growing suburbs are also lucrative markets.
These markets have been key as the company focused on treating higher-acuity patients, those needing more complex and potentially more lucrative care. Over the past few years, HCA has invested in more complex service lines, CEO Sam Hazen said during a recent earnings call with investors.
For example, HCA’s six bone marrow transplant programs grew volume by 17% last year, Hazen told investors, and trauma volume increased by 7%. He said there’s still room to add or expand service lines, citing electrophysiology and cardiac.
The chain’s robust network of outpatient facilities helps capture market share and ultimately push those higher-acuity patients to the area’s HCA hospitals, Megan Neuburger, managing director at Fitch Ratings, told Healthcare Dive.
“Relative to their peers, they were earlier in the trends that they needed to build out a continuum of care within their communities,” Neuburger said.
HCA has upward of 130 urgent care facilities, more than Tenet and CHS. HCA also outpaces those competitors on free-standing ERs, with 84 of its own, according to year-end numbers the companies recently shared. These ancillary services can drive revenue, particularly free-standing ERs, which tend to be extremely costly compared to a traditional physician office visit.
It’s an area HCA continues to invest in, Hazen said. “Those are small dollar capital items and they don’t consume a huge amount of our budget. So they are very efficient from that standpoint,” Hazen said of investment in outpatient facilities such as urgent care centers, surgery centers and free-standing ERs. 

Competitor strategies

It doesn’t hurt that one of HCA’s biggest rivals, Community Health Systems, has stumbled in recent years following the $7.6 billion acquisition of Naples, Florida-based HMA in 2014.  HMA was found guilty of false billing and physician kickbacks, which CHS admitting to knowing before acquiring the company in 2014
But CHS has changed its strategy to improve performance and margins, investing in more populated areas.
“We are no longer a non-urban, or a rural hospital company,” CHS chairman and CEO Wayne Smith said during J.P. Morgan’s annual healthcare conference in January.
CHS has focused on moving into areas with a population greater than 50,000. By the end of the year, 95% of its facilities will be located in areas with populations greater than 50,000 — areas that also have improved unemployment rates, Smith said. “Our markets are looking a lot more like HCA and Universal and Tenet than they did in the past,” he said.
Another big for-profit chain, Tenet, has been struggling with declining patient volumes as it tries to trim its debt load. On the company’s most recent earnings call, CEO Ron Rittenmeyer said Tenet is entering 2019 with a renewed sense of urgency around volume growth. That was after he said during the previous quarter that the company’s volume growth, or lack of, was “not acceptable” and that its hospitals “did not meet our expectations and we are focusing on specific areas to address those gaps.”
As Tenet’s patient volumes have faced continued pressure, the Dallas-based operator has remained committed to its strategy of exiting markets if it’s not the No. 1 or No. 2 player in terms of market share. It has also undergone a restructuring effort that eliminated layers of management and other overhead costs.
Nothing lasts forever, and HCA is not totally immune to big market trends, Fitch said in a recent note.
“Secular trends, including a shift to lower-cost care driven by health insurer scrutiny, increasing healthcare consumerism, and growth in Medicare patient volumes outpacing growth of patients with commercial health insurance, will be headwinds to organic growth and profitability,” the ratings agency said.
Fitch did warn that any changes to the ACA that results in more uninsured or underinsured patients could “result in a weaker payor mix for acute care hospitals, which would pressure margins.”
While repeal and replace legislation seems unlikely, given the split powers in Congress, a federal judge in Texas deemed the ACA unconstitutional in December. While many experts think the ruling will be overturned, it will take time to play out through the court system. The case is now in front of the U.S. Court of Appeals for the 5th Circuit after Democratic state attorneys general appealed the ruling out of Texas.

Whistleblowers allege Community Health made false claims about EHR tech

A whistleblower accused Franklin, Tenn.-based Community Health Systems of submitting hundreds of millions of dollars in false claims to HHS for federal incentive payments for meaningfully using electronic health records.
The lawsuit, unsealed by a federal court in Miami on Thursday, claimed that CHS made it a priority for its hospitals to submit attestations for incentive payments because they were an important source of revenue for the system. The two whistleblowers, who worked for CHS as recently as December 2016, allege the for-profit system received more than $450 million in EHR incentive payments between 2012 and 2015.
HHS makes Medicare and Medicaid incentive payments to hospitals and physicians that demonstrate meaningful use of certified EHR technology through the Promoting Interoperability Program, which was formerly known as meaningful use. To qualify for incentive payments, hospitals and clinicians have to attest that they used certified technology and satisfied certain program objectives.
“Even though the flaws and lack of reliability with both the Medhost software and CHS’ implementation of the software should have made the CHS hospitals ineligible for Meaningful Use incentive payments, CHS and CHS hospitals knowingly misrepresented to the government that the hospitals were eligible for subsidy payments,” the complaint states.
In a statement, CHS said it believes the whistleblower allegations are “without merit” and “has complete confidence that all of its meaningful use attestations have been accurate.” 
The federal government has not yet intervened in the lawsuit, saying it has not completed its investigation by the court’s deadline and is not yet able to decide whether to proceed, according to a notice filed with the court on Tuesday. The notice stated that the government would continue its investigation.
The software implemented at CHS hospitals and developed by vendor Medhost, who is also named as a defendant in the complaint, contained flaws that prevented clinicians from providing care safely and reliably, making the software ineligible for certification under the incentive program, the complaint alleges. CHS implemented the EHR software rapidly to be able to reap more incentive payments, which led to additional problems with the software’s performance and endangered patients, the lawsuit alleges.
For example, the complaint says problems with the EHR technology led doctors to inadvertently order incorrect medications or dosages. The technology also was unable to trigger medications to be delivered at the right time, perform drug interaction checks or lock patient charts while open, according to the complaint.
“Some of the defects in the software, including an inability to calculate weight-based dosing accurately, exposed patients to mistakes that were easily missed in institutional settings and potentially catastrophic,” the complaint said.
CHS said in its statement that it worked diligently to address any issues with the EHR technology and is unaware of any instances of patient harm.
Doctors and hospital administrators sounded the alarm about the flaws, but CHS continued to roll out the software across its hospitals. CHS and Medhost then knowingly and falsely attested that the software complied with certification requirements, the complaint alleges.
The complaint further alleges that the 60 hospitals CHS acquired from Health Management Associates similarly did not meet certification requirements, yet CHS knowingly attested the software did.

Allergan to Present New Data at Glaucoma Meet

Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, will present new data including a late-breaking abstract for Bimatoprost SR at the Annual Meeting of the American Glaucoma Society (AGS) to be held in San Francisco, California.
The late-breaking abstract, to be presented for the first time during a podium session on Saturday, March 16th, is the initial treatment duration analysis of Phase 3 clinical data for Bimatoprost SR, a first-in-class sustained-release, biodegradable implant being evaluated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Topline Phase 3 efficacy and safety results from the ongoing studies will also be presented at a congress later this year. Allergan anticipates submitting a New Drug Application (NDA) to the FDA in the second half of 2019.
‘This first presentation showing the treatment duration from the Phase 3 studies confirms that Bimatoprost SR could represent a major paradigm shift in the management of glaucoma. Bimatoprost SR demonstrated an extended duration of effect in many patients, and the potential for most patients to need no additional treatment for one year after three administrations of the implant,’ said Yehia Hashad, MD, Vice President and Global Head, Clinical Development, Eye Care, Allergan. ‘The development of Bimatoprost SR demonstrates our continued commitment to developing innovative therapies for glaucoma, a progressive disease that requires consistent IOP control to preserve vision for patients.’
Allergan will present two abstracts, including one podium presentation (accepted as a late-breaking abstract) and one poster presentation (all noted in local Pacific Standard Time)

ACC Preview: Apple Watch, Cardiac Device Trials, Keto Diet

As the American College of Cardiology annual meeting opens in New Orleans this weekend, one of the big stories will undoubtedly be on the role of wrist sensors, such as the Apple Watch, in identifying heart rhythm problems. There will be other big stories, of course. Here’s a preview of just a couple.
Apple-Sponsored Study
Stanford University researchers will kick off the meeting with a very large study of more than 400,000 patients in a study sponsored by Apple. They will present the results of whether the Apple Watch can accurately detect heart rhythm problems. Dubbed the Apple Heart Study, the trial had 419,297 participants, described as “a research study conducted to evaluate whether the Apple Heart Study App can use data collected on the Apple Watch to identify irregular heart rhythms, including those from potentially serious heart conditions such as atrial fibrillation.”
The patients participating wear the Apple Watch and are sent a notification if the smartwatch detected an irregular heartbeat. They were then followed up with an ECG for verification.
“I think this study is of considerable interest both to consumers who wear these devices but also physicians who are caring for these patients,” Pamela Morris, co-chair of the meeting and physician with the Medical University of South Carolina, Charleston, told TCTMD, publication of the Cardiovascular Research Forum (CRF). “We know atrial fibrillation is associated with an increased risk of stroke and other clotting events, but sometimes [the A-fib] is asymptomatic for patients, which is where these devices could come in, in recognizing rhythm disturbance.”
PARTNER 3 Trial and the Medtronic-Sponsored CoreValve or Evolut Trial
The Apple study will be followed by two sessions on Sunday focusing on TAVR low-risk trials, two COAPT analyses, and a TVT/STS registry analysis of balloon-expandable TAVR devices in bicuspid valve disease, reports TCTMD. One is results from the PARTNER 3 clinical trial, sponsored by Edwards Lifesciences. Data on the Sapien 3 device with surgery in about 1,300 patients at low risk for surgical aortic valve replacement, will be presented.
Right after that data is presented, there will be a presentation of data on a Medtronic-sponsored trial of 1,200 low-risk patients who received surgery or transcatheter replacement using the CoreValve or Evolut devices.

Interventional Cardiology Trials
On Monday, research will be presented, according to TCTMD, including “a comparison of femoral versus radial access for STEMI and two studies looking at single versus dual antiplatelet therapy following DES implantation (STOPDAPT-2 and SMART-CHOICE). COACT, meanwhile, is investigating the role of an early invasive strategy in post-cardiac arrest patients without STEMI, a group in whom the value of early angiography is uncertain.”
There will also be research presented on Sunday focusing on interventional studies, including data from DEFINE PCI, a blinded physiological analysis of residual ischemia after PCI, one-year data from the ADVANCE registry, evaluating the impact of FFRCT, and the MRUSMI first-in-man clinical trial on sonothrombolysis in STEMI patients undergoing PCI.
Low-Carb Dies Like Keto May Cause AFib
In what is likely to gather a lot of attention in the consumer media, research will be presented suggesting that low-carbohydrate diets, such as the Keto diet, may increase the risk of atrial fibrillation (AFib). People with AFib are five times more likely to have a stroke and are also at risk for heart attacks.
“The long-term effect of carbohydrate restriction is still controversial, especially with regard to its influence on cardiovascular disease,” stated Xiaodong Zhuang, a cardiologist at a hospital affiliated with National Sun Yat-Sen University in Guangzhou, China. “Considering the potential influence on arrhythmia, our study suggests this popular weight control method should be recommended cautiously.”
The study, which drew on data from the National Institutes of Health (NIH) that collected data over a decade, looked at 13,852 people, none of whom had AFib at the beginning. At the end of the study, 1,892 were diagnosed with AFib. Split into three groups with low, moderate and high carbohydrate diets, the study found that the low-carb group had the highest risk for developing AFib, 18 percent more than those who ate moderate carbs and 16 percent more than those in the high-intake group.
Those studies and many more will be presented at the meeting.

Bayer Animal Health draws interest from KKR, CVC, Bloomberg reports

Bayer (BAYRY) is proceeding with plans to sell its animal health unit as large private equity firms like KKR (KKR) and CVC Capital weigh bids, Bloomberg reports, citing people familiar with the matter. The business may also draw interest from buyout firms such as Advent International, Blackstone (BX), EQT Partners, and Permira as well as industry competitors, the report says. The unit could fetch as much as $9B, the report notes.
https://thefly.com/landingPageNews.php?id=2880089

Stryker acquires OrthoSpace and its rotator cuff implant in $220M deal

Stryker has acquired OrthoSpace, developers of a therapy for severely torn rotator cuffs, in a deal worth up to $220 million, split evenly between upfront cash and future milestone payments.
The Israel-based OrthoSpace has developed a biodegradable balloon spacer that fits between the shoulder’s scapula and acromonion bones, as well as the humerus of the arm, to realign the natural mechanics of the shoulder, reduce pain and improve range of motion.
The InSpace balloon allows the bones to move with less friction, and mimics the shoulder’s bursa, a fluid-filled cushion that sits between the shoulder bones. The minimally invasive treatment is currently undergoing clinical development in the U.S., and is not yet approved.
“The acquisition of OrthoSpace is highly complementary to our existing portfolio and aligns with Stryker’s focus on investing in sports medicine,” Stryker’s Med-Surg group president, Andy Pierce, said in a statement.
However, it might take some time to see a return: the company said it does not expect the purchase to add much to its net earnings in 2019.
“We are excited about the momentum OrthoSpace has in key global markets and the additional surgical option this technology provides our customers to address a complex pathology,” Pierce said.
To date, the CE-marked InSpace balloon has been used in outpatient procedures for massive, irreparable tears in more than 20,000 patients in 30 countries, the companies said.
OrthoSpace raised $8 million in funding for a U.S. pivotal study in 2015, followed by another $7 million a year later—including money from Johnson & Johnson Innovation, Smith & Nephew, TriVentures and HealthpointCapital.